1L Gastric Cancers
IMABI-MabCatalyst overview
Research summary
This catalyst tracks a Phase 1b data readout for Givastomig (TJ-CD4B/ABL111) combo w/ nivolumab + chemo in 1L Gastric Cancers. The expected timing is based on the latest available company guidance and may change.
04/07/26:- Ph1b meeting data and possible Ph3 start expected in Q4 2026. 06/16/26:- FDA Fast Track granted. Detailed Ph1b data expected at major conference in H2 2026. Ph3 may start Q4 2026. 08/20/26:- Positive Ph1b data reiterated. ESMO 2026 data presentation will occur October 25, 2026. Registrational Ph3 initiation is expected as early as YE 2026. Ph3 interim data readout is planned in 2028.
Verification
Confirm timing and program details against the company announcement or filing.